IXC 16.9% 9.0¢ invex therapeutics ltd

Ann: Phase II Clinical Results and Capital Raising Presentation, page-21

ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
  1. 1,257 Posts.
    lightbulb Created with Sketch. 12374
    95% would make the margins cross further. The presentation makes a point of stating the statistical significance of the pressure sensor that they are using. Unless they have used a lot of data to clearly define the 2.5 hour data set (which is because there are many 2.5 hour post medication measures within the 12 weeks) and could only use 16 data points at the 12 week mark. I think having a larger data set would help with defining the 12 week or shall I say the medium to long term effects. Very expected to have such a large 90% CI if only 16 data points have been used for 12 weeks.
 
watchlist Created with Sketch. Add IXC (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.